Form 4: Acrivon CDO Withholds Shares for Tax on RSUs

Chief Development Officer Erick Gamelin withheld 403 ACRV shares at $2.24 to cover taxes upon RSU vesting, leaving 15,283 shares owned directly.

Summary

• Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), reported a transaction on 11/14/2025 coded “F” (tax withholding related to equity vesting).
• A total of 403 common shares were withheld at a price of $2.24 to satisfy mandatory tax withholding requirements upon vesting of restricted stock units (RSUs).
• Post-transaction, Gamelin directly owns 15,283 ACRV shares.
• The transaction was not an open market buy or sell and reflects administrative share withholding for taxes.
• The document was signed by Attorney-in-Fact Adam D. Levy on 11/18/2025.

Sentiment

Score: 5

Explanation: Neutral, routine administrative transaction with no evident implications for fundamentals or outlook.

Positives

• Routine, non-discretionary tax withholding (Code F) rather than an open market sale.
• Executive maintains a direct ownership position of 15,283 shares following the transaction.

Negatives

• Direct holdings decreased by 403 shares as part of tax withholding on RSU vesting.

Future Outlook

None provided.

Management Comments

• Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Industry Context

Administrative insider transactions tied to RSU vesting and tax withholding are common across biotech and broader public markets and generally carry limited signaling value regarding company outlook.

Comparison to Industry Standards

• Use of SEC transaction code F for RSU tax withholding is standard practice and not indicative of discretionary buying or selling.
• Share withholding (issuer-facilitated) is a typical alternative to open-market ‘sell-to-cover’ transactions often seen across biotech peers.

Stakeholder Impact

• Administrative tax withholding rather than an open market sale, suggesting minimal signaling value.
• Executive continues to hold 15,283 shares directly following the RSU-related withholding.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, insider transaction, Form 4, RSU vesting, tax withholding, Erick Gamelin, Chief Development Officer, biotechnology, executive compensation